OSE Immunotherapeutics SA (LON:0RAD)
5.70
-0.29 (-4.85%)
At close: Apr 23, 2025
OSE Immunotherapeutics Revenue
In the year 2024, OSE Immunotherapeutics had annual revenue of 83.44M EUR with 3,646.52% growth. OSE Immunotherapeutics had revenue of 862.00K in the half year ending December 31, 2024, a decrease of -61.77%.
Revenue
83.44M EUR
Revenue Growth
+3,646.52%
P/S Ratio
1.55
Revenue / Employee
1.52M EUR
Employees
55
Market Cap
106.98M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 83.44M | 81.21M | 3,646.52% |
Dec 31, 2023 | 2.23M | -16.08M | -87.83% |
Dec 31, 2022 | 18.30M | -8.00M | -30.43% |
Dec 31, 2021 | 26.31M | 15.89M | 152.48% |
Dec 31, 2020 | 10.42M | -15.53M | -59.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
HSBC Holdings | 48.93B |
Shell | 227.10B |
Unilever | 50.25B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |
British American Tobacco p.l.c. | 25.87B |
Rolls-Royce Holdings | 18.91B |